Cargando…

Current status and perspectives in immunotherapy for metastatic melanoma

Metastatic melanoma was the first malignancy in which immune checkpoint inhibitors demonstrated their successful efficacy. Currently, the knowledge on the interaction between the immune system and malignant disease is steadily increasing and new drugs and therapeutic strategies are overlooking in th...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marconcini, Riccardo, Spagnolo, Francesco, Stucci, Luigia Stefania, Ribero, Simone, Marra, Elena, Rosa, Francesco De, Picasso, Virginia, Di Guardo, Lorenza, Cimminiello, Carolina, Cavalieri, Stefano, Orgiano, Laura, Tanda, Enrica, Spano, Laura, Falcone, Alfredo, Queirolo, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844761/ https://www.ncbi.nlm.nih.gov/pubmed/29552325 http://dx.doi.org/10.18632/oncotarget.23746

Ejemplares similares

BRAF-mutant melanoma: treatment approaches, resistance mechanisms, and diagnostic strategies
por: Spagnolo, Francesco, et al.
Publicado: (2015)

Immunotherapy for the Treatment of Cutaneous Squamous Cell Carcinoma
por: Boutros, Andrea, et al.
Publicado: (2021)

Combined vemurafenib and fotemustine in patients with BRAF V600 melanoma progressing on vemurafenib
por: Queirolo, Paola, et al.
Publicado: (2016)

Merkel Cell Carcinoma: An Immunotherapy Fairy-Tale?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

Investigating the role of immunotherapy in advanced/recurrent female genital tract melanoma: a preliminary experience
por: Indini, Alice, et al.
Publicado: (2019)

Combination of immunotherapy and other targeted therapies in advanced cutaneous melanoma
por: Marconcini, Riccardo, et al.
Publicado: (2021)

Treatment beyond progression with anti-PD-1/PD-L1 based regimens in advanced solid tumors: a systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Clinical, pathological and dermoscopic phenotype of MITF p.E318K carrier cutaneous melanoma patients
por: Ciccarese, Giulia, et al.
Publicado: (2020)

Immunotherapy in Adolescents and Young Adults: What Remains in Cancer Survivors?
por: Tanda, Enrica Teresa, et al.
Publicado: (2021)

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort
por: Ascierto, Paolo A, et al.
Publicado: (2014)

An Italian Retrospective Survey on Bone Metastasis in Melanoma: Impact of Immunotherapy and Radiotherapy on Survival
por: Mannavola, Francesco, et al.
Publicado: (2020)

Case Report: Immune-Related Toxicity During Adjuvant Treatment With BRAF Plus MEK Inhibitors in a Melanoma Patient
por: Boutros, Andrea, et al.
Publicado: (2020)

Non-BRAF Mutant Melanoma: Molecular Features and Therapeutical Implications
por: Vanni, Irene, et al.
Publicado: (2020)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

How to Make Immunotherapy an Effective Therapeutic Choice for Uveal Melanoma
por: Marseglia, Mariarosaria, et al.
Publicado: (2021)

The Current State of Molecular Testing in the BRAF-Mutated Melanoma Landscape
por: Vanni, Irene, et al.
Publicado: (2020)

Current State of Target Treatment in BRAF Mutated Melanoma
por: Tanda, Enrica Teresa, et al.
Publicado: (2020)

Whole-Exome Sequencing and cfDNA Analysis Uncover Genetic Determinants of Melanoma Therapy Response in a Real-World Setting
por: Vanni, Irene, et al.
Publicado: (2023)

Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases
por: Queirolo, Paola, et al.
Publicado: (2014)

Comparison Between First Line Target Therapy and Immunotherapy in Different Prognostic Categories of BRAF Mutant Metastatic Melanoma Patients: An Italian Melanoma Intergroup Study
por: Marconcini, Riccardo, et al.
Publicado: (2022)

Patients with locally advanced and metastatic cutaneous squamous cell carcinoma treated with immunotherapy in the era of COVID-19: stop or go? Data from five Italian referral cancer centers
por: Saponara, Maristella, et al.
Publicado: (2020)

Harnessing host innate immunity may combat acquired resistance to BRAFi
por: Tan, Thomas, et al.
Publicado: (2014)

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma
por: Spagnolo, Francesco, et al.
Publicado: (2014)

Cutaneous Events Associated with Immunotherapy of Melanoma: A Review
por: Burzi, Lorenza, et al.
Publicado: (2021)

Sequential treatment with ipilimumab and BRAF inhibitors in patients with metastatic melanoma: data from the Italian ipilimumab expanded access programme (EAP)
por: Ascierto, Paolo Antonio, et al.
Publicado: (2013)

Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
por: Chiarion Sileni, Vanna, et al.
Publicado: (2014)

Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2017)

Correction: Combining molecular and immunohistochemical analyses of key drivers in primary melanomas: interplay between germline and somatic variations
por: Bruno, William, et al.
Publicado: (2018)

Influenza vaccination in cancer patients receiving immune checkpoint inhibitors: A systematic review
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Immune system and melanoma biology: a balance between immunosurveillance and immune escape
por: Passarelli, Anna, et al.
Publicado: (2017)

Metastatic BRAF K601E-mutated melanoma reaches complete response to MEK inhibitor trametinib administered for over 36 months
por: Marconcini, Riccardo, et al.
Publicado: (2017)

Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren: Analysis of the educational campaign “Il Sole Amico” (“The sun as a friend”)
por: Stanganelli, Ignazio, et al.
Publicado: (2020)

Heterogeneity and frequency of BRAF mutations in primary melanoma: Comparison between molecular methods and immunohistochemistry
por: Bruno, William, et al.
Publicado: (2016)

Ataxia-Telangiectasia Mutated Loss of Heterozygosity in Melanoma
por: Pastorino, Lorenza, et al.
Publicado: (2022)

PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC
por: Del Re, Marzia, et al.
Publicado: (2018)

Role of teledermatology in the management of dermatological diseases among marine workers: A cross-sectional study comparing general practitioners and dermatological diagnoses
por: Di Canio, Marzio, et al.
Publicado: (2022)

Cerivastatin Synergizes with Trametinib and Enhances Its Efficacy in the Therapy of Uveal Melanoma
por: Amaro, Adriana Agnese, et al.
Publicado: (2023)

Long-term exposure and health risk assessment from air pollution: impact of regional scale mobility
por: Gilardi, Lorenza, et al.
Publicado: (2023)

PD-1/PD-L1 checkpoint inhibitors during late stages of life: an ad-hoc analysis from a large multicenter cohort
por: Santini, Daniele, et al.
Publicado: (2021)

Radiological findings in non-surgical recurrent hepatocellular carcinoma: From locoregional treatments to immunotherapy
por: Ippolito, Davide, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cf2l69fs66o47qogv79dreui51